Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#380 of 589

Andreas Argyrides

Oppenheimer · Equity Research Analyst
ProvisionalRating since 2024No new ratings since Nov 2025

Analyst rating accuracy & track record

Andreas Argyrides is an equity research analyst at Oppenheimer. Quantellect has scored 29 of their stock calls across 17 companies. Their picks beat their sector 41% of the time over the next 12 months, and their price targets were reached 33% of the time within a year.

Win % vs sector
41%
PT Hit % (12mo)
33%
Avg sector-excess
−9.0%
Scored calls
29
Tickers
17
Tier
Provisional

Track record

Quantellect has scored 29 of Andreas Argyrides's stock calls across 17 companies, dating back to 2024. Their rated stocks beat their own sector 41% of the time over the next 12 months. On a typical call, a Argyrides pick returned −9.0% more than its sector over the following year.

Of the scored calls, 28 were bullish (Buy) and 1 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
KROSKeros Therapeutics Inc
Buy$27.00Nov 2025−65.7%Miss
LRMRLarimar Therapeutics Inc
Buy$21.00Oct 2025−54.9%Miss
MNPRMonopar Therapeutics Inc
Buy$115.00Oct 2025−37.3%Hit
BNTCBenitec Biopharma Inc.
Buy$29.00Sep 2025−42.8%Miss
KALAKala Pharmaceuticals Inc
Buy$33.00Sep 2025−121.2%Miss
SVRASavara Inc
Buy$8.00Sep 2025+22.6%Miss
MNKDMannKind Corp
Buy$15.00Sep 2025−48.1%Miss
MNPRMonopar Therapeutics Inc
Buy$77.00Sep 2025+177.5%Hit
ABEOAbeona Therapeutics Inc
Buy$20.00Aug 2025−38.6%Miss
KALAKala Pharmaceuticals Inc
Buy$15.00Aug 2025−129.5%Hit
KALAKala Pharmaceuticals Inc
Buy$750.00Aug 2025−129.5%Miss
DYNDyne Therapeutics Inc
Buy$13.00Aug 2025+102.2%Hit
HRMYHarmony Biosciences Holdings
Buy$61.00Jun 2025−24.5%Miss
KALAKala Pharmaceuticals Inc
Buy$15.00Jun 2025−110.8%Hit
AQSTAquestive Therapeutics Inc
Buy$7.00Jun 2025+11.6%Hit
ABEOAbeona Therapeutics Inc
Buy$19.00Jun 2025−21.3%Miss
DYNDyne Therapeutics Inc
Buy$34.00Jun 2025+17.9%Miss
IFRXInflaRx N.V.
Buy$3.00May 2025+184.4%Miss
LQDALiquidia Technologies Inc
Sell$13.00May 2025−241.1%Hit
RANIRani Therapeutics Holdings Inc
Buy$4.00May 2025+28.5%Miss
KRROKorro Bio, Inc.
Buy$90.00May 2025−36.6%Miss
PRQRProQR Therapeutics BV
Buy$9.00May 2025−6.3%Miss
IFRXInflaRx N.V.
Buy$6.00May 2025+50.2%Miss
KROSKeros Therapeutics Inc
Buy$23.00Jan 2025+60.6%Miss
KROSKeros Therapeutics Inc
Buy$63.00Dec 2024+7.0%Miss
Prev1
Go to

Andreas Argyrides: analyst track record FAQ

Is Andreas Argyrides a good stock analyst?

Yes, by track record. Andreas Argyrides ranks number 380 of 589 of the analysts Quantellect scores, with an Analyst Score of 23 out of 100. Past results do not guarantee future ones.

What is Andreas Argyrides's win rate?

Andreas Argyrides's win rate is 41%. Across 29 scored calls, their rated stocks beat their sector 41% of the time over the next 12 months. On a typical call they returned −9.0% more than the sector.

What stocks and sectors does Andreas Argyrides cover?

Andreas Argyrides covers 17 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Andreas Argyrides's price targets accurate?

Andreas Argyrides's price targets are reached within 12 months 33% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Andreas Argyrides's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Andreas Argyrides rank among Wall Street analysts?

Andreas Argyrides ranks number 380 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.